Abstract

Food allergy is documented to result in considerable morbidity, negative impact on quality of life, and substantial medical care costs. Although anecdotal data suggest widely varying practices in the diagnosis and management of food allergies, the diversity and relative frequency of these practices have not been documented. A questionnaire was developed evaluating allergists' management approaches of individuals with peanut allergy (PA) in Germany (DE), France (FR), and the United Kingdom (UK). Here, we report the survey results from a total of 109 allergists from DE, FR and the UK. They reported to confirm PA at initial diagnosis using skin prick test (≥60%), while allergists from DE and FR reported using allergen-specific IgE testing more (>86%) compared to the UK (<50%). At initial diagnosis, oral food challenge was used less in DE (13%) and FR (14%) and very rarely in the UK (3%) to confirm diagnosis. Recognition of acute reactions, use of adrenaline auto-injectors and allergen avoidance were reported to be discussed with the patient/caregiver at the initial office visit by most allergists (>75%). Half of the responders reported assessing the patient's quality of life. 63% allergists reported retesting for PA resolution at a later date, with 45% allergists indicated to recommend ingestion of a normal serving of peanut regularly upon resolution. Lack of effective PA treatment was reported to be a 'very significant' barrier for optimal PA treatment, with allergists being less than 'moderately familiar' with data from clinical trials testing new treatments options for PA. Lastly, allergists stated that the severity of patient's PA ranked as the most important factor in their decision to recommend oral immunotherapy for PA treatment. This survey provides essential insights into the practice of allergists and highlights some areas that would inform strategies for education and improving PA healthcare.

Highlights

  • The prevalence of food allergy (FA), and especially an allergy to peanuts, has increased in developed countries in recent years [1]

  • Half of the responders reported assessing the patient’s quality of life. 63% allergists reported retesting for peanut allergy (PA) resolution at a later date, with 45% allergists indicated to recommend ingestion of a normal serving of peanut regularly upon resolution

  • At the time of this publication, standardised oral biologic drug–PTAH (Peanut [Arachis hypogaea] allergen powder-dnfp) formally called AR101, was approved by the US Food and Drug Administration (January 2020) as the first oral immunotherapy (OIT) indicated to mitigate allergic reactions following accidental exposure to peanuts in individuals aged 4–17 years with a confirmed diagnosis of PA [12], and was not approved by any other regulatory authorities. Despite their high awareness about the Learning Early About Peanut Allergy (LEAP) study for the early introduction of dietary peanut for high-risk allergic infants [13], and modified National Institute of Allergy and Infectious Diseases guidelines, a survey reported that many paediatricians continue to have guideline implementation barriers [14]

Read more

Summary

Results

We report the survey results from a total of 109 allergists from DE, FR and the UK. They reported to confirm PA at initial diagnosis using skin prick test ( 60%), while allergists from DE and FR reported using allergen-specific IgE testing more (>86%) compared to the UK (

Introduction
Study participants
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call